z-logo
Premium
Erratum to “Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration”
Publication year - 2021
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.33544
Subject(s) - medicine , food and drug administration , cancer drugs , drug , drug approval , intensive care medicine , drug administration , cancer , pharmacology

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom